What Today’s USMCA Debate Has to Do with The Drugs of Tomorrow
The political winds seem to be blowing in favor of a Congressional vote on the U.S.-Mexico-Canada Free Trade Agreement (USMCA) yet this fall. But before they vote, some Members of Congress want to talk over a few issues with the Trump administration’s negotiators. One is intellectual property protections for the U.S. biopharmaceutical industry. As important as it is, the issue of data protection for biologic drugs is not well understood.